Search

CAMPBELL, Calif., Jan. 8, 2020 /PRNewswire/ -- KDx Diagnostics, Inc. (KDx), announced today that the Food and Drug Administration (FDA) has granted "Breakthrough Device" designation for its URO17™ Bladder Cancer Recurrence Test...more

20 views

Bladder carcinoma is a common urological cancer with high morbidity, mortality, and recurrence rates requiring frequent, invasive diagnostic procedures...more(1)more(2) 

11 views

A new biomarker allows effective, noninvasive screening of patients at risk of the disease. Bladder cancer presents a diagnostic challenge for even the best pathologists and laboratory medicine professionals...more

2 views